JP3433231B2 - 胃ガンのリスクのスクリーニング方法 - Google Patents
胃ガンのリスクのスクリーニング方法Info
- Publication number
- JP3433231B2 JP3433231B2 JP51577496A JP51577496A JP3433231B2 JP 3433231 B2 JP3433231 B2 JP 3433231B2 JP 51577496 A JP51577496 A JP 51577496A JP 51577496 A JP51577496 A JP 51577496A JP 3433231 B2 JP3433231 B2 JP 3433231B2
- Authority
- JP
- Japan
- Prior art keywords
- gastrin
- pepsinogen
- atrophy
- serum
- gastric cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 46
- 208000005718 Stomach Neoplasms Diseases 0.000 title claims abstract description 26
- 206010017758 gastric cancer Diseases 0.000 title claims abstract description 26
- 201000011549 stomach cancer Diseases 0.000 title claims abstract description 26
- 238000012216 screening Methods 0.000 title claims abstract description 12
- 102400000921 Gastrin Human genes 0.000 claims abstract description 54
- GKDWRERMBNGKCZ-RNXBIMIWSA-N gastrin-17 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 GKDWRERMBNGKCZ-RNXBIMIWSA-N 0.000 claims abstract description 38
- 210000002966 serum Anatomy 0.000 claims abstract description 38
- 108010066264 gastrin 17 Proteins 0.000 claims abstract description 36
- 108010047320 Pepsinogen A Proteins 0.000 claims abstract description 35
- 206010003694 Atrophy Diseases 0.000 claims abstract description 21
- 230000037444 atrophy Effects 0.000 claims abstract description 21
- 210000002784 stomach Anatomy 0.000 claims abstract description 15
- 241000590002 Helicobacter pylori Species 0.000 claims abstract description 13
- 229940037467 helicobacter pylori Drugs 0.000 claims abstract description 13
- 210000004877 mucosa Anatomy 0.000 claims abstract description 4
- 108010052343 Gastrins Proteins 0.000 claims description 20
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 claims description 20
- 238000005259 measurement Methods 0.000 claims description 13
- 210000001156 gastric mucosa Anatomy 0.000 claims description 12
- 239000000427 antigen Substances 0.000 claims description 10
- 102000036639 antigens Human genes 0.000 claims description 10
- 108091007433 antigens Proteins 0.000 claims description 10
- 241000283973 Oryctolagus cuniculus Species 0.000 claims description 6
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 238000012360 testing method Methods 0.000 claims description 6
- 238000002965 ELISA Methods 0.000 claims description 5
- 241001494479 Pecora Species 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 3
- 229960002685 biotin Drugs 0.000 claims description 3
- 239000011616 biotin Substances 0.000 claims description 3
- 230000001900 immune effect Effects 0.000 claims description 3
- 238000004020 luminiscence type Methods 0.000 claims description 3
- 230000003053 immunization Effects 0.000 claims description 2
- 230000031700 light absorption Effects 0.000 claims description 2
- 238000011896 sensitive detection Methods 0.000 claims description 2
- 235000000891 standard diet Nutrition 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims 2
- 241000282887 Suidae Species 0.000 claims 1
- 229920002678 cellulose Polymers 0.000 claims 1
- 239000001913 cellulose Substances 0.000 claims 1
- 238000001917 fluorescence detection Methods 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000003993 interaction Effects 0.000 claims 1
- 238000000504 luminescence detection Methods 0.000 claims 1
- 238000000691 measurement method Methods 0.000 claims 1
- 239000004033 plastic Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000002575 gastroscopy Methods 0.000 abstract description 7
- 206010019375 Helicobacter infections Diseases 0.000 abstract description 4
- 208000007882 Gastritis Diseases 0.000 description 17
- 206010028980 Neoplasm Diseases 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 208000016644 chronic atrophic gastritis Diseases 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 210000000746 body region Anatomy 0.000 description 7
- 208000004300 Atrophic Gastritis Diseases 0.000 description 6
- 208000036495 Gastritis atrophic Diseases 0.000 description 6
- 108010014475 Pepsinogens Proteins 0.000 description 6
- 102000023022 Pepsinogens Human genes 0.000 description 6
- 230000035945 sensitivity Effects 0.000 description 6
- 208000023652 chronic gastritis Diseases 0.000 description 5
- 230000028327 secretion Effects 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 101800000285 Big gastrin Proteins 0.000 description 4
- 102400000948 Big gastrin Human genes 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- FMIHGWZLPSIAFY-WGFKALLTSA-N gastrin-34 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCC(N)=O)C(C)C)C1=CC=C(O)C=C1 FMIHGWZLPSIAFY-WGFKALLTSA-N 0.000 description 4
- 210000004400 mucous membrane Anatomy 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 108090001072 Gastricsin Proteins 0.000 description 3
- 102000034255 Pepsinogen C Human genes 0.000 description 3
- 208000031845 Pernicious anaemia Diseases 0.000 description 3
- 208000006994 Precancerous Conditions Diseases 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000011088 calibration curve Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002183 duodenal effect Effects 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000004907 gland Anatomy 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 206010058314 Dysplasia Diseases 0.000 description 2
- 206010017807 Gastric mucosal hypertrophy Diseases 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 241000589989 Helicobacter Species 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 208000000239 Hypertrophic Gastritis Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010067994 Mucosal atrophy Diseases 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 235000020958 biotin Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- XZKIHKMTEMTJQX-UHFFFAOYSA-N 4-Nitrophenyl Phosphate Chemical compound OP(O)(=O)OC1=CC=C([N+]([O-])=O)C=C1 XZKIHKMTEMTJQX-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 235000007754 Achillea millefolium Nutrition 0.000 description 1
- 240000000073 Achillea millefolium Species 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 206010003504 Aspiration Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000035985 Body Odor Diseases 0.000 description 1
- 210000000712 G cell Anatomy 0.000 description 1
- 206010017817 Gastric polyps Diseases 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000034525 Ménétrier disease Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 238000008330 Pyloriset EIA-G Methods 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 206010040904 Skin odour abnormal Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010046274 Upper gastrointestinal haemorrhage Diseases 0.000 description 1
- 230000009858 acid secretion Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000001660 aspiration Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 210000000465 brunner gland Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 210000004691 chief cell of stomach Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- SSBRJDBGIVUNDK-QOGDCIHTSA-N gastrin-14 Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CC=C(O)C=C1 SSBRJDBGIVUNDK-QOGDCIHTSA-N 0.000 description 1
- OKGNKPYIPKMGLR-ZPCKCTIPSA-N gastrins Chemical class C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1NC(=O)CC1)C1=CN=CN1 OKGNKPYIPKMGLR-ZPCKCTIPSA-N 0.000 description 1
- 239000003629 gastrointestinal hormone Substances 0.000 description 1
- 230000000762 glandular Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 108010076432 minigastrin Proteins 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- NKAAEMMYHLFEFN-UHFFFAOYSA-M monosodium tartrate Chemical compound [Na+].OC(=O)C(O)C(O)C([O-])=O NKAAEMMYHLFEFN-UHFFFAOYSA-M 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- RZIMNEGTIDYAGZ-HNSJZBNRSA-N pro-gastrin Chemical compound N([C@@H](CC(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)NCC(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CC(O)=O)C(=O)NCC(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N1CCC[C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)C(=O)[C@@H]1CCC(=O)N1 RZIMNEGTIDYAGZ-HNSJZBNRSA-N 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000021025 protein-rich diet Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 210000000582 semen Anatomy 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 208000018556 stomach disease Diseases 0.000 description 1
- 238000006177 thiolation reaction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 230000001515 vagal effect Effects 0.000 description 1
- 230000002861 ventricular Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57446—Specifically defined cancers of stomach or intestine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B10/00—Other methods or instruments for diagnosis, e.g. instruments for taking a cell sample, for biopsy, for vaccination diagnosis; Sex determination; Ovulation-period determination; Throat striking implements
- A61B10/0045—Devices for taking samples of body liquids
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI945391A FI97304C (fi) | 1994-11-16 | 1994-11-16 | Menetelmä mahasyövän riskin seulonnaksi |
| FI945391 | 1994-11-16 | ||
| PCT/FI1995/000634 WO1996015456A1 (en) | 1994-11-16 | 1995-11-15 | Method for screening the risk of gastric cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH10509795A JPH10509795A (ja) | 1998-09-22 |
| JP3433231B2 true JP3433231B2 (ja) | 2003-08-04 |
Family
ID=8541817
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP51577496A Expired - Fee Related JP3433231B2 (ja) | 1994-11-16 | 1995-11-15 | 胃ガンのリスクのスクリーニング方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6696262B2 (es) |
| EP (1) | EP0804737B1 (es) |
| JP (1) | JP3433231B2 (es) |
| AT (1) | ATE213332T1 (es) |
| AU (1) | AU3874395A (es) |
| DE (1) | DE69525476T2 (es) |
| DK (1) | DK0804737T3 (es) |
| ES (1) | ES2171564T3 (es) |
| FI (1) | FI97304C (es) |
| PT (1) | PT804737E (es) |
| WO (1) | WO1996015456A1 (es) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011501177A (ja) * | 2007-10-26 | 2011-01-06 | ビオヒット・ユルキネン・オサケユキテュア | 自己免疫疾患および萎縮性胃炎と関連する胃癌を診断するための方法および製品 |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6861510B1 (en) * | 1989-01-24 | 2005-03-01 | Aphton Corporation | Immunogenic compositions against gastrin peptides |
| DK0889735T3 (da) * | 1996-02-08 | 2011-08-08 | Cancer Advances Inc | Immunogene metoder til behandling af gastrointestinal cancer |
| US20040001842A1 (en) * | 1997-05-12 | 2004-01-01 | Dov Michaeli | Immunogenic compositions to the CCK-B/gastrin receptor and methods for the treatment of tumors |
| ATE361098T1 (de) * | 1998-05-15 | 2007-05-15 | Receptor Biologix Inc | Vorbeugung und behandlung von hypergastrinemie |
| US6372439B2 (en) | 1998-10-01 | 2002-04-16 | James R. Goldenring | Screen for gastric adenocarcinoma |
| EP1121597A1 (en) * | 1998-10-01 | 2001-08-08 | Medical College of Georgia Research Institute | Screen for risk for gastric adenocarcinoma |
| FI990991A (fi) * | 1999-04-30 | 2000-10-31 | Locus Genex Oy | Menetelmä irreversiibeleille neurovahingoille riskialttiin yksikön identifioimiseksi |
| FI118653B (fi) | 1999-04-30 | 2008-01-31 | Biohit Oyj | Menetelmä peptisen haavan riskin määrittämiseksi |
| FI107808B (fi) * | 1999-08-31 | 2001-10-15 | Biohit Oyj | Menetelmä verisuoni- sekä syöpäsairaudelle riskialttiin yksilön identifioimiseksi |
| AU2001253024A1 (en) * | 2000-04-10 | 2001-10-23 | The General Hospital Corporation | Diagnosis and treatment of gastrointestinal disease |
| US7179609B1 (en) * | 2000-10-04 | 2007-02-20 | Atrophus Ab | Screening method for gastritis |
| FI20010019A (fi) | 2001-01-05 | 2002-07-06 | Biohit Oyj | Menetelmä atrofisen diagnostisoimiseksi |
| CA2441228A1 (en) * | 2001-03-23 | 2002-10-03 | Aphton Corporation | Combination treatment of pancreatic cancer |
| US20090191232A1 (en) * | 2001-05-04 | 2009-07-30 | Gevas Philip C | Combination therapy for the treatment of tumors |
| JP4763149B2 (ja) * | 2001-05-10 | 2011-08-31 | わかもと製薬株式会社 | ヘリコバクター・ピロリへの感染を判定する検査方法 |
| CA2450898A1 (en) * | 2001-07-09 | 2003-01-23 | Aphton Corporation | Treatment and prevention of cancerous and pre-cancerous conditions of the liver, lung and esophagus |
| FI20011908A (fi) * | 2001-09-28 | 2003-03-29 | Biohit Oyj | Menetelmä vatsasyövän osoittamiseksi |
| JP4689597B2 (ja) * | 2003-03-28 | 2011-05-25 | レセプター バイオロジックス インク． | ガストリンホルモン免疫アッセイ |
| FI119572B (fi) * | 2004-03-05 | 2008-12-31 | Biohit Oyj | Menetelmä vatsan limakalvon tilan ennustamiseksi |
| WO2005095459A2 (en) * | 2004-03-29 | 2005-10-13 | Receptor Biologix, Inc. | Monoclonal antibodies to gastrin hormone |
| FI116942B (fi) * | 2004-05-10 | 2006-04-13 | Biohit Oyj | Proteiini- ja peptidistabilointi |
| CA2580965C (en) | 2004-09-22 | 2014-04-08 | Receptor Biologix, Inc. | Monoclonal antibodies to progastrin |
| ES2732623T3 (es) | 2005-01-06 | 2019-11-25 | Innate Pharma Sa | Tratamientos y métodos de combinación anti-KIR |
| US20070207467A1 (en) * | 2006-03-01 | 2007-09-06 | Ming Xu | Detection of lymph node metastasis from gastric carcinoma |
| FI20060501L (fi) * | 2006-05-22 | 2007-11-23 | Biohit Oyj | Koostumus ja menetelmä asetaldehydin sitomiseksi vatsassa |
| US20070281305A1 (en) * | 2006-06-05 | 2007-12-06 | Sean Wuxiong Cao | Detection of lymph node metastasis from gastric carcinoma |
| CN102087279A (zh) * | 2010-03-11 | 2011-06-08 | 北京美康生物技术研究中心 | 一种联合诊断胃病或评价胃癌风险的酶联免疫吸附试剂盒 |
| RU2465597C1 (ru) * | 2011-04-08 | 2012-10-27 | Сергей Михайлович Котелевец | Способ определения вероятности развития рака желудка |
| GB201121571D0 (en) | 2011-12-15 | 2012-01-25 | Astrimmune Ltd | Compounds and uses thereof |
| CN113514647A (zh) * | 2014-06-13 | 2021-10-19 | 拜奥希特公司 | 胃泌素-17作为具有增加的数种相关后发病风险的萎缩性胃炎的生物标志物的用途 |
| ES2810760T3 (es) * | 2015-02-10 | 2021-03-09 | Shenzhen New Ind Biomedical Engineering Co Ltd | Kit de reactivos utilizado para detectar gastrina-17 y método de preparación y aplicación para el kit de reactivos |
| CN106501532B (zh) * | 2016-10-14 | 2019-02-19 | 北京正旦国际科技有限责任公司 | 一种用于检测胃泌素17的试剂盒 |
| JP6885581B2 (ja) * | 2017-02-06 | 2021-06-16 | 学校法人東京歯科大学 | ガストリン測定におけるカットオフ値の推定方法 |
| JP7469225B2 (ja) | 2017-06-15 | 2024-04-16 | キャンサー アドヴァンシーズ インク． | 腫瘍及び癌に対する体液性及び細胞性免疫を誘発するための組成物及び方法 |
| RU2677228C1 (ru) * | 2017-12-08 | 2019-01-16 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Национальный исследовательский Мордовский государственный университет им. Н.П. Огарёва" | Способ иммунодиагностики заболеваний гастродуоденальной зоны |
| CN109991409B (zh) * | 2018-12-03 | 2022-03-04 | 浙江聚康生物工程有限公司 | 胃蛋白酶原i/胃蛋白酶原ii检测试剂盒 |
| FI20205255A1 (en) | 2020-03-11 | 2021-09-12 | Biohit Oyj | Gastrin-17 test for screening for dyspepsia and reflux symptoms, and atrophic gastritis, and related risks |
| CN111638369B (zh) * | 2020-04-30 | 2023-03-31 | 吉林省格瑞斯特生物技术有限公司 | 胃功能及胃癌发生风险的荧光微球检测装置及其制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2949474B2 (ja) * | 1995-08-28 | 1999-09-13 | 隆久 古田 | ペプシノーゲンｉ／ｉｉ比の変化率を基礎としたヘリコバクター・ピロリ除菌判定方法 |
-
1994
- 1994-11-16 FI FI945391A patent/FI97304C/fi not_active IP Right Cessation
-
1995
- 1995-11-15 ES ES95937917T patent/ES2171564T3/es not_active Expired - Lifetime
- 1995-11-15 JP JP51577496A patent/JP3433231B2/ja not_active Expired - Fee Related
- 1995-11-15 PT PT95937917T patent/PT804737E/pt unknown
- 1995-11-15 DK DK95937917T patent/DK0804737T3/da active
- 1995-11-15 AU AU38743/95A patent/AU3874395A/en not_active Abandoned
- 1995-11-15 EP EP95937917A patent/EP0804737B1/en not_active Expired - Lifetime
- 1995-11-15 AT AT95937917T patent/ATE213332T1/de not_active IP Right Cessation
- 1995-11-15 WO PCT/FI1995/000634 patent/WO1996015456A1/en active IP Right Grant
- 1995-11-15 DE DE69525476T patent/DE69525476T2/de not_active Expired - Lifetime
-
2001
- 2001-03-14 US US09/809,549 patent/US6696262B2/en not_active Expired - Lifetime
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011501177A (ja) * | 2007-10-26 | 2011-01-06 | ビオヒット・ユルキネン・オサケユキテュア | 自己免疫疾患および萎縮性胃炎と関連する胃癌を診断するための方法および製品 |
Also Published As
| Publication number | Publication date |
|---|---|
| PT804737E (pt) | 2002-07-31 |
| US6696262B2 (en) | 2004-02-24 |
| FI97304C (fi) | 1996-11-25 |
| FI945391A (fi) | 1996-05-17 |
| US20010039025A1 (en) | 2001-11-08 |
| FI945391A0 (fi) | 1994-11-16 |
| ES2171564T3 (es) | 2002-09-16 |
| AU3874395A (en) | 1996-06-06 |
| ATE213332T1 (de) | 2002-02-15 |
| FI97304B (fi) | 1996-08-15 |
| EP0804737B1 (en) | 2002-02-13 |
| DK0804737T3 (da) | 2002-04-29 |
| JPH10509795A (ja) | 1998-09-22 |
| WO1996015456A1 (en) | 1996-05-23 |
| DE69525476T2 (de) | 2002-10-02 |
| DE69525476D1 (de) | 2002-03-21 |
| EP0804737A1 (en) | 1997-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3433231B2 (ja) | 胃ガンのリスクのスクリーニング方法 | |
| Lähteenoja et al. | Oral mucosal changes in | |
| Ruoslahti et al. | Studies of carcino‐fetal proteins. III. Development of a radioimmunoassay for α‐fetoprotein. Demonstration of α‐fetoprotein in serum of healthy human adults | |
| JP4834839B2 (ja) | 悪性黒色腫（メラノーマ）の新規な診断キット | |
| JP4598959B2 (ja) | 血清サンプル中のペプシノーゲンｉ（ｐｇｉ）とガストリン−１７の濃度の定量的測定の段階を含む、消化性潰瘍の危険性を評価する方法 | |
| Albrecht et al. | Detection of circulating tissue factor and factor VII in a normal population | |
| US20200064346A1 (en) | Mmp-8 activation product, its determination and use | |
| Kelly et al. | Mucosal and systemic IgA anti-gliadin antibody in celiac disease: contrasting patterns of response in serum, saliva, and intestinal secretions | |
| US20070087395A1 (en) | Method for detecting pathogenic organisms in fecal and salivary specimens and in biopsy material | |
| Höglund et al. | Epidemiology of Anoplocephala perfoliata infection in foals on a stud farm in south-western Sweden | |
| US4241044A (en) | Method of diagnosing cancer by detecting elevated anti-T antibody activity | |
| JP4602078B2 (ja) | ヒト心不全における血漿ウロテンシン | |
| EP1552311B1 (en) | Method for detecting a risk of acid related disease in an individual | |
| Hayakawa et al. | Pancreatic stone protein and lactoferrin in human pancreatic juice in chronic pancreatitis | |
| Pals et al. | Enzyme-linked immunosorbent assay and radioimmunoassay of serum pepsinogen A | |
| JPS59501519A (ja) | 炭水化物抗原決定基のための免疫検定 | |
| Watanabe | Immunochemical and immunohistochemical studies on chronic paranasal sinus infection | |
| WO2018155793A1 (ko) | En2 단백질의 면역원성 단편 펩타이드 또는 이를 특이적으로 인식하는 항체 조성물 | |
| JP2018021882A (ja) | 歯周病の検査方法 | |
| Harel et al. | MEASUREMENT OF ELASTIN DEGRADATION IN VIVO BY DESMOSINE RADIOIMMUNOASSAY: MESURE DE LA DÉGRADATION DE L'ÉLASTINE IN VIVO PAR DOSAGE RADIO-IMMUNOLOGIQUE DE LA DESMOSINE | |
| Abd-Alsaheb et al. | The Role of Helicobacter pylori in Induction of Gastric Autoimmunity | |
| PETERSEN et al. | Abnormal processing of antral gastrin in active duodenal ulcer disease | |
| WO2003029826A1 (en) | Method for detecting a cancer or precancerous condition | |
| WO2016080777A1 (ko) | Odam의 치주질환 바이오마커로서의 용도 | |
| JPH0785085B2 (ja) | フイブロネクチン測定試薬 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090530 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090530 Year of fee payment: 6 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100530 Year of fee payment: 7 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110530 Year of fee payment: 8 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130530 Year of fee payment: 10 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |